Alison T Stopeck

Summary

Affiliation: University of Arizona
Country: USA

Publications

  1. ncbi The role of targeted therapy and biomarkers in breast cancer treatment
    Alison T Stopeck
    University of Arizona Cancer Center, 1515N Campbell Avenue, Tucson, AZ 85724, USA
    Clin Exp Metastasis 29:807-19. 2012
  2. ncbi A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515
    Alison T Stopeck
    University of Arizona Cancer Center, Tucson, AZ, USA
    Blood 120:1210-7. 2012
  3. ncbi Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States
    Alison Stopeck
    University of Arizona Cancer Center, Tucson, AZ 85724 5024, USA
    J Med Econ 15:712-23. 2012
  4. ncbi Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study
    Alison T Stopeck
    University of Arizona, Arizona Cancer Center, Tucson, AZ, USA
    J Clin Oncol 28:5132-9. 2010
  5. ncbi Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma
    A T Stopeck
    Section of Hematology Oncology, Arizona Cancer Center, University of Arizona, Tucson 85724, USA
    J Clin Oncol 15:341-9. 1997
  6. ncbi A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108
    Alison T Stopeck
    Arizona Cancer Center, University of Arizona, Tucson, AZ 85724 5024, USA
    Leuk Lymphoma 50:728-35. 2009
  7. ncbi Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma
    A T Stopeck
    Department of Medicine, Arizona Cancer Center, University of Arizona, Tucson 85724, USA
    Clin Cancer Res 6:3904-9. 2000
  8. ncbi Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma
    A T Stopeck
    Arizona Cancer Center, 1515 North Campbell Avenue, Tucson, AZ 85724, USA
    Clin Cancer Res 7:2285-91. 2001
  9. ncbi Radial fast spin-echo method for T2-weighted imaging and T2 mapping of the liver
    Maria I Altbach
    Department of Radiology, University of Arizona, Tucson, Arizona 85724, USA
    J Magn Reson Imaging 16:179-89. 2002
  10. ncbi Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial
    Patricia A Thompson
    Arizona Cancer Center, University of Arizona, Tucson, 85724 5024, USA
    Cancer Prev Res (Phila) 3:101-7. 2010

Research Grants

  1. DIFFUSION MRI AS BIOMARKER FOR THERAPY RESPONSE IN BREAST CANCER METASTASES
    Alison Stopeck; Fiscal Year: 2007
  2. DIFFUSION MRI AS BIOMARKER FOR THERAPY RESPONSE IN BREAST CANCER METASTASES
    Alison Stopeck; Fiscal Year: 2009
  3. DIFFUSION MRI AS BIOMARKER FOR THERAPY RESPONSE IN BREAST CANCER METASTASES
    Alison T Stopeck; Fiscal Year: 2010

Detail Information

Publications18

  1. ncbi The role of targeted therapy and biomarkers in breast cancer treatment
    Alison T Stopeck
    University of Arizona Cancer Center, 1515N Campbell Avenue, Tucson, AZ 85724, USA
    Clin Exp Metastasis 29:807-19. 2012
    ..Using these as examples, many of the innovations and challenges in the treatment of women with breast cancer are explored...
  2. ncbi A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515
    Alison T Stopeck
    University of Arizona Cancer Center, Tucson, AZ, USA
    Blood 120:1210-7. 2012
    ..This study is registered at www.clinicaltrials.gov as #NCT00121199...
  3. ncbi Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States
    Alison Stopeck
    University of Arizona Cancer Center, Tucson, AZ 85724 5024, USA
    J Med Econ 15:712-23. 2012
    ..This study sought to determine the lifetime cost-effectiveness of denosumab vs ZA in this setting, from a US managed-care perspective...
  4. ncbi Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study
    Alison T Stopeck
    University of Arizona, Arizona Cancer Center, Tucson, AZ, USA
    J Clin Oncol 28:5132-9. 2010
    ....
  5. ncbi Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma
    A T Stopeck
    Section of Hematology Oncology, Arizona Cancer Center, University of Arizona, Tucson 85724, USA
    J Clin Oncol 15:341-9. 1997
    ....
  6. ncbi A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108
    Alison T Stopeck
    Arizona Cancer Center, University of Arizona, Tucson, AZ 85724 5024, USA
    Leuk Lymphoma 50:728-35. 2009
    ..Clinical trials combining active chemotherapy regimens with VEGF targeted agents are currently in progress...
  7. ncbi Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma
    A T Stopeck
    Department of Medicine, Arizona Cancer Center, University of Arizona, Tucson 85724, USA
    Clin Cancer Res 6:3904-9. 2000
    ....
  8. ncbi Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma
    A T Stopeck
    Arizona Cancer Center, 1515 North Campbell Avenue, Tucson, AZ 85724, USA
    Clin Cancer Res 7:2285-91. 2001
    ..Clinical trials optimizing patient selection and combining Allovectin-7 with other modalities of therapy are currently ongoing in an effort to improve response rates...
  9. ncbi Radial fast spin-echo method for T2-weighted imaging and T2 mapping of the liver
    Maria I Altbach
    Department of Radiology, University of Arizona, Tucson, Arizona 85724, USA
    J Magn Reson Imaging 16:179-89. 2002
    ..To evaluate a multishot radial fast-spin echo (RAD-FSE) method developed to improve the quality of abdominal T2-weighted imaging as well as the characterization of focal liver lesions...
  10. ncbi Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial
    Patricia A Thompson
    Arizona Cancer Center, University of Arizona, Tucson, 85724 5024, USA
    Cancer Prev Res (Phila) 3:101-7. 2010
    ..038). These results are the first to show partitioning of sulindac and metabolites to human breast tissue and the first evidence for a potential dose-dependent effect of sulindac on growth differentiation factor 15 levels in NAF...
  11. ncbi A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer
    Michael S Gordon
    Premiere Oncology, Scottsdale, AZ, USA
    Cancer 113:3420-9. 2008
    ..The current study was designed to establish the safety of ABT-510 in the treatment of patients with advanced malignancies on a once-daily (QD) and twice-daily dosing schedule...
  12. ncbi Changes in body weight and metabolic indexes in overweight breast cancer survivors enrolled in a randomized trial of low-fat vs. reduced carbohydrate diets
    Cynthia A Thomson
    University of Arizona, Tucson, Arizona 85721, USA
    Nutr Cancer 62:1142-52. 2010
    ..1 ± 36.6; P = 0.01). Significant improvements in weight and metabolic indexes can be demonstrated among overweight breast cancer survivors adherent to either a carbohydrate- or fat-restricted diet...
  13. ncbi Task-based evaluation of segmentation algorithms for diffusion-weighted MRI without using a gold standard
    Abhinav K Jha
    College of Optical Sciences, University of Arizona, Tucson, AZ, USA
    Phys Med Biol 57:4425-46. 2012
    ..The method can be used to rank the segmentation algorithms on the basis of both the ensemble mean square error and precision. We also propose consistency checks for this evaluation technique...
  14. ncbi Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors
    Ursa Brown-Glaberman
    University of Arizona Cancer Center, Tucson, AZ, USA
    Biologics 6:89-99. 2012
    ....
  15. ncbi Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast
    Julia A Coronella
    Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
    J Immunol 169:1829-36. 2002
    ..These data suggest an in situ Ag-driven oligoclonal B cell response to a variety of tumor- and breast-associated Ags...
  16. ncbi Caring for the breast cancer survivor: a guide for primary care physicians
    Pavani Chalasani
    Arizona Cancer Center, University of Arizona, Tucson, AZ 85724 5024, USA
    Am J Med 123:489-95. 2010
    ..Current strategies for screening, monitoring, and treating these complications also are outlined...
  17. ncbi Women's health: the struggle to restore hormonal balance
    Alison T Stopeck
    Am J Med 118:1181-2. 2005
  18. ncbi Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5410-7. 2007
    ..This phase I study examined whether a heat shock protein (Hsp) 90 inhibitor tanespimycin (17-AAG; KOS-953) could be administered safely in combination with trastuzumab at a dose that inhibits Hsp90 function in vivo in lymphocytes...

Research Grants5

  1. DIFFUSION MRI AS BIOMARKER FOR THERAPY RESPONSE IN BREAST CANCER METASTASES
    Alison Stopeck; Fiscal Year: 2007
    ....
  2. DIFFUSION MRI AS BIOMARKER FOR THERAPY RESPONSE IN BREAST CANCER METASTASES
    Alison Stopeck; Fiscal Year: 2009
    ....
  3. DIFFUSION MRI AS BIOMARKER FOR THERAPY RESPONSE IN BREAST CANCER METASTASES
    Alison T Stopeck; Fiscal Year: 2010
    ....